Lawyers USA Your Business Partner

FDA: New label for anti-smoking drug Chantix 

Published: August 9, 2011

Tags: black box warning, Chantix, drug labeling, drug litigation, FDA, Food and Drug Administration, smoking

The Food and Drug Administration has announced that the label for the smoking cessation drug Chantix will be updated to address the effect of the drug on users with cardiovascular disease.

Discovery expanded in Yaz, Yasmin multidistrict litigation 

Published: August 3, 2011

Tags: Bayer, birth control, Discovery, drug litigation, failure to warn, MDL, multidistrict litigation, Yasmin, Yaz

Discovery in the multidistrict litigation over the birth control drugs Yaz/Yasmin has been expanded beyond the 24 selected bellwether cases.

Panel weighs consolidation of Darvon/Darvocet litigation 

By: Sylvia Hsieh
Published: July 29, 2011

Tags: Darvocet, Darvon, drug litigation, Eli Lilly, MDL, multidistrict litigation, PLIVA v. Mensing

SAN FRANCISCO – In oral arguments before the multidistrict litigation panel on Thursday in San Francisco, lawyers sparred over whether litigation involving the popular pain medications Darvon and Darvocet should be consolidated and if so, where they should be centralized.

In drug tort suits, it’s a name game 

By: Kimberly Atkins
Published: July 5, 2011

Tags: drug litigation, generic drugs, preemption, Supreme Court

WASHINGTON – The Supreme Court ruling late last month that state-law failure-to-warn claims against generic drug makers are preempted by federal law – handed down just two years after the Court held that brand-name drug makers could face such suits – creates a legal discrepancy that leaves the majority of patients without recourse, some advocates say.

Plaintiff wins verdict over contaminated Heparin 

Published: June 30, 2011

Tags: Baxter, drug litigation, Heparin

An Illinois jury has awarded $625,000 to the estate of a man who died after being given a contaminated form of the blood thinner Heparin during dialysis.

Generic drug failure-to-warn claims ruled preempted 

Published: June 23, 2011

Tags: drug litigation, generic drugs, metoclopramide, preemption, Supreme Court, tardive dyskinesia

Federal drug regulations governing generic drugs directly conflict with, and thus preempt, state-law failure-to-warn claims, the U.S. Supreme Court has ruled.

PREEMPTION 

Published: June 23, 2011

Tags: drug litigation, generic drugs, metoclopramide, preemption, Supreme Court, tardive dyskinesia

Federal drug regulations governing generic drugs directly conflict with, and thus preempt, state-law failure-to-warn claims, the U.S. Supreme Court has ruled.

See “Generic drug failure-to-warn claims preempted”

U.S. Supreme Court. PLIVA, Inc. v. Mensing, No. 09-1501. June 23, 2011. Lawyers USA No. 993-3033.

Report: Chantix risks underestimated 

Published: May 27, 2011

Tags: Avandia, Chantix, drug litigation, drug safety, FDA, Food and Drug Administration, Pfizer, suicide

A product liability watchdog claims that the risks of Pfizer’s quit-smoking drug Chantix have been underestimated in the latest reporting by the Food and Drug Administration.

Plavix cases start to pick up 

By: Sylvia Hsieh
Published: May 18, 2011

Tags: drug litigation, FDA, Food and Drug Administration, Plavix

Litigation over the blood thinner Plavix is picking up momentum.

Accutane verdicts: $2 million for one plaintiff out of three 

By: Correy Stephenson
Published: April 22, 2011

Tags: Accutane, Crohn’s disease, drug litigation, failure to warn, Hoffman-LaRoche, IBD, inflammatory bowel disease

In a trio of cases tried together against Hoffman-LaRoche, the maker of Accutane, jurors awarded just one of the plaintiffs suffering from inflammatory bowel disease $2.1 million.